Patents by Inventor Stanislaw M. Mikulski

Stanislaw M. Mikulski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR
    Publication number: 20140357620
    Abstract: There are provided a new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Inventors: John Frederick Boylan, Stanislaw M. Mikulski
  • COMBINATION THERAPY
    Publication number: 20120184529
    Abstract: The present invention relates to a combination therapy of 2-Chloro-N-(4-chloro-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide and 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N?-(2,2,3,3,3-pentafluoro-propyl)-malonamide for treating a patient suffering from a proliferative disorder.
    Type: Application
    Filed: January 3, 2012
    Publication date: July 19, 2012
    Inventors: Mark D. DeMario, Stanislaw M. Mikulski
  • Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells
    Patent number: 6290951
    Abstract: A first substance (such as the peptide aldehydes LLnL and LVP) inhibits the function of intracellular proteasome. A second substance (such as ranpirnase) inhibits intracellular protein synthesis or increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor. Both substances are administered in such a manner that the effects thereof are coincident. The cell cycle of affected tumor cells is therefore arrested and the cells die of apoptosis.
    Type: Grant
    Filed: August 1, 1998
    Date of Patent: September 18, 2001
    Assignee: Alfacell Corporation
    Inventor: Stanislaw M. Mikulski
  • Compositions comprising ONCONASE (tm) and lovastatin
    Patent number: 5595734
    Abstract: A pharmaceutical known by the trademark ONCONASE, as described in pending commonly owned application application number 07/436,141 filed Nov. 13, 1989, is combined with two forms of another drug known as Lovastatin. The combination of ONCONASE with Lovastatin has unexpected bioactivity in vitro against ASPC-1 human pancreatic adenocarcinoma cells, A-549 human lung carcinoma cells and HT-520 human squamous cell lung carcinoma cells.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: January 21, 1997
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Compositions comprising ONCONASE (TM) and STELAZINE (TM) or TAMOXIFEN (TM)
    Patent number: 5540925
    Abstract: A pharmaceutical to be sold under the ONCONASE trademark, as described in pending commonly owned application application Ser. No. 07/436,141 filed Nov. 13, 1989 is combined with other drugs sold under the trademarks TAMOXIFEN and STELAZINE. The combination of ONCONASE with TAMOXIFEN has unexpected bioactivity in vitro against ASPC-1 human pancreatic adenocarcinoma cells and the combination of ONCONASE with STELAZINE has unexpected bioactivity in vitro against A-549 human lung carcinoma cells.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: July 30, 1996
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Compositions comprising ONCONASE(.TM.) and cisplatin, melphalan, or doxorubicin HCl
    Patent number: 5529775
    Abstract: A pharmaceutical known by the trademark ONCONASE, as described in pending commonly owned application application Ser. No. 07/436,141 filed Nov. 13, 1989, is combined with drugs sold under the names cisplatin, Melphalan and Doxorubicin HCl. The combinations of ONCONASE with these drugs has unexpected bioactivity in vitro against OVCAR-3 human ovarian adenocarcinoma cells.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: June 25, 1996
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Pharmaceutical for treating tumors and method for making it
    Patent number: 4882421
    Abstract: Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography.The resulting pharmaceutical has activity against certain cancer cells. A partial amino acid sequence of the pharmaceutical is disclosed.
    Type: Grant
    Filed: April 6, 1988
    Date of Patent: November 21, 1989
    Assignee: Alfacell Corporation
    Inventors: Kuslima Shogen, Stanislaw M. Mikulski, Wojciech J. Ardelt